The public health need and present status of a vaccine for the prevention of coccidioidomycosis.
Although the epidemiology of coccidioidomycosis has been well described, there is a paucity of recent data on the public health burden associated with this disease. Accordingly, California's Inpatient Hospital Discharge Data Set from 1997 to 2002 was used to calculate the incidence of hospitalization for coccidioidomycosis by county, year, age, race, ethnicity, and gender. The overall finding that coccidioidomycosis has a significant impact in endemic areas supports the conclusion that the need for a preventive vaccine is great. Investigators of the Valley Fever Vaccine Project (VFVP) have successfully identified a number of recombinant coccidioidal protein antigens and two attenuated mutant strains that have been evaluated as vaccines, demonstrating protective responses in murine models. Efforts to select and develop a vaccine for human clinical trials are in progress.
Hector
Richard
R
Institute for Global Health, University of California, San Francisco, 50 Beale St., Suite 1200, San Francisco, CA 94105, USA. rhector@psg.ucsf.edu
Rutherford
George W
GW
D000946:Antigens, Fungal / Q000737:chemistry; D002140:California; D003047:Coccidioidomycosis / Q000453:epidemiology / Q000517:prevention & control* / Q000628:therapy*; D005657:Fungal Vaccines / Q000737:chemistry* / Q000627:therapeutic use*; D006301:Health Services Needs and Demand; D006753:Hospital Records; D006801:Humans; D007107:Immune System; D015994:Incidence; D008828:Microbiological Techniques; D011634:Public Health; D011994:Recombinant Proteins / Q000737:chemistry; D012106:Research / Q000639:trends; D014611:Vaccination
D000946:Antigens, Fungal; D005657:Fungal Vaccines; D011994:Recombinant Proteins